Further research is required to clarify the exact mechanisms involved in the role of OX-40 in the progression of CTCL, as well as to determine its potential synergistic effects with other available therapies. The gene discussed is TNFRSF4; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.